Skip to main content
SpringerLink
Log in

Secukinumab provides good value for money for AS

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Purmonen T, et al. Efficacy-Based Budget Impact Analysis of Secukinumab vs Adalimumab in the Treatment of Ankylosing Spondylitis in Finland. 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS16, 4 Nov 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/76811?pdfid=52918.

  2. Kooli A, et al. Secukinumab vs Adalimumab for the Treatment of Ankylosing Spondylitis: a Cost Per Responder Analysis at 52 Weeks from a Moroccan Perspective. 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS28, 4 Nov 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/78673?pdfid=52841.

  3. Gunda P, et al. A Cost Per Responder Analysis of Secukinumab vs. Adalimumab Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Ankylosing Spondylitis at 52 Weeks from the Irish Payer Perspective. 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS38, 4 Nov 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/76029?pdfid=52645.

  4. Chiva-Razavi S, et al. Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis: a Canadian Perspective. 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS43, 4 Nov 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/77776?pdfid=52221.

  5. Emery P, et al. Cost-Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMS44, 4 Nov 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/78476?pdfid=52019.

  6. Sarioz F, et al. Secukinumab is Dominant vs. Tnf-Inhibitors in the Treatment of Active Ankylosing Spondylitis: Results from a Turkish Cost-Effectiveness Model. 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PMS47, 4 Nov 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/76166?pdfid=52119.

  7. Barbeau M, et al. Secukinumab vs. Adalimumab for Treatment of Ankylosing Spondylitis: a Cost Per Responder Analysis at 52 Weeks from an Argentinian Perspective. 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PMS50, 4 Nov 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/75553?pdfid=51790.

  8. Patino A, et al. Secukinumab as a More Efficient Alternative for the Treatment of Ankylosing Spondylitis: a Cost Per Responder Analysis Versus Adalimumab and Golimumab from a Peruvian Perspective for Private and Public Health Schemes. 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSY60, 4 Nov 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/78485?pdfid=52296.

  9. Patino A, et al. Secukinumab as a More Efficient Alternative for the Treatment of Ankylosing Spondylitis: a Cost Per Responder Analysis Versus Adalimumab and Golimumab from a Colombian Perspective. 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSY61, 4 Nov 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/78510?pdfid=52295.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Secukinumab provides good value for money for AS. PharmacoEcon Outcomes News 793, 29–30 (2017). https://doi.org/10.1007/s40274-017-4589-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4589-0

Search

Navigation